Möchten Sie immer auf dem neuesten Stand bleiben?

Steroid use reduction and disease control: In additional results from the Phase 3 PHOENYCS GO study, dapirolizumab pegol (DZP) plus standard of care was associated with sustained disease control at...

Publication adds to previously reported findings from Phase 3 PHOENYCS GO study, demonstrating statistically significant improvement in disease activity at Week 48 with dapirolizumab pegol plus...

In the Phase 2 part of the AMETHYST study, litifilimab met the primary endpoint of reduction of disease activity in people living with CLE at Week 16, with more litifilimab participants achieving...

Late-breaking AMETHYST Part A study results to be presented, showing safety and efficacy of litifilimab in cutaneous lupus erythematosus (CLE)Litifilimab was recently granted Breakthrough Therapy...

Designation is based on the breadth of available litifilimab data, including the Phase 2 LILAC study result that showed improvements in cutaneous lupus erythematosus (CLE) skin disease...

SOUTH SAN FRANCISCO, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to...

Dapirolizumab pegol (DZP) Phase 3 study presentations in SLE to show efficacy results across multiple clinical endpoints, including low disease activity/remission, flares, fatigue, joint pain and...

Belleville, Illinois, Sept. 05, 2025 (GLOBE NEWSWIRE) -- — Allsup, the nation’s premier disability representation company®, is proud to be a silver sponsor of the “2025 Walk To End Lupus Now, St....

EXTON, PA, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Spherix Global Insights announces the upcoming release of its latest Special Topix™ service, Payer Management Strategies, providing pharmaceutical...

$3M NIH grant advances TRE-515, a first-in-class lupus therapy. Funding supports safety, biomarker studies, and paves the way for patient trials.